Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years
1Intestinal Disease Research Unit, Faculty of Medicine, University of Calgary, Alberta, Canada.
Abstract:
As we approach the 100th year since the introduction of aspirin to the marketplace, the association of gastrointestinal damage with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) remains the major limitation to their use. Although various approaches have been taken to producing NSAIDs with reduced gastrointestinal toxicity, few have significantly reduced the incidence of clinically significant adverse reactions (perforation or hemorrhage). In this review, the mechanisms contributing to the mucosal injury caused by NSAIDs in the stomach, small intestine, and colon are reviewed. In addition, several recent strategies for developing NSAIDs that spare the gastrointestinal tract of injury are discussed. These include selective inhibitors of cyclooxygenase 2, nitric oxide-releasing NSAIDs, and NSAIDs preassociated with zwitterionic phospholipids.
More Related Videos
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
08:56Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
Published on: November 30, 2022
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Ulcerative Colitis
